Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James H Roger

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Biostatistics (Oxford, England)|November 17, 2009
The use of baseline covariates in crossover studiesMichael G Kenward, James H Roger
Pharmaceutical Statistics|July 16, 2024
Handling Partially Observed Trial Data After Treatment Withdrawal: Introducing Retrieved Dropout Reference-Base Centred Multiple ImputationSuzie Cro, James H Roger, James R Carpenter
Pharmaceutical Statistics|March 29, 2007
Practical usage of O'Brien's OLS and GLS statistics in clinical trialsNigel S Dallow, Sergei L Leonov, James H Roger
Journal of Biopharmaceutical Statistics|October 22, 2013
Analysis of longitudinal trials with protocol deviation: a framework for relevant, accessible assumptions, and inference via multiple imputationJames R Carpenter, James H Roger, Michael G Kenward
Pharmaceutical Statistics|April 17, 2024
Comments on 'standard and reference-based conditional mean imputation': Regulators and trial statisticians be aware!Suzie Cro, Tim P Morris, James H Roger, et al.
Pharmaceutical Statistics|June 17, 2014
Missing data sensitivity analysis for recurrent event data using controlled imputationOliver N Keene, James H Roger, Benjamin F Hartley, et al.
Pharmaceutical Statistics|November 9, 2018
Treatment policy estimands for recurrent event data using data collected after cessation of randomised treatmentJames H Roger, Daniel J Bratton, Bhabita Mayer, et al.
Plos One|January 30, 2014
Platelet aggregation unchanged by lipoprotein-associated phospholipase A₂ inhibition: results from an in vitro study and two randomized phase I trialsBonnie C Shaddinger, Yanmei Xu, James H Roger, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Biostatistics (Oxford, England)|November 17, 2009
The use of baseline covariates in crossover studiesMichael G Kenward, James H Roger
Pharmaceutical Statistics|July 16, 2024
Handling Partially Observed Trial Data After Treatment Withdrawal: Introducing Retrieved Dropout Reference-Base Centred Multiple ImputationSuzie Cro, James H Roger, James R Carpenter
Pharmaceutical Statistics|March 29, 2007
Practical usage of O'Brien's OLS and GLS statistics in clinical trialsNigel S Dallow, Sergei L Leonov, James H Roger
Journal of Biopharmaceutical Statistics|October 22, 2013
Analysis of longitudinal trials with protocol deviation: a framework for relevant, accessible assumptions, and inference via multiple imputationJames R Carpenter, James H Roger, Michael G Kenward
Pharmaceutical Statistics|April 17, 2024
Comments on 'standard and reference-based conditional mean imputation': Regulators and trial statisticians be aware!Suzie Cro, Tim P Morris, James H Roger, et al.
Pharmaceutical Statistics|June 17, 2014
Missing data sensitivity analysis for recurrent event data using controlled imputationOliver N Keene, James H Roger, Benjamin F Hartley, et al.
Pharmaceutical Statistics|November 9, 2018
Treatment policy estimands for recurrent event data using data collected after cessation of randomised treatmentJames H Roger, Daniel J Bratton, Bhabita Mayer, et al.
Plos One|January 30, 2014
Platelet aggregation unchanged by lipoprotein-associated phospholipase A₂ inhibition: results from an in vitro study and two randomized phase I trialsBonnie C Shaddinger, Yanmei Xu, James H Roger, et al.
Pageof 1